Ciltacabtagene autoleucel, a BCMA directed CAR-T therapy, in relapsed refractory multiple myeloma: Updated results from CARTITUDE-1

Dr. Saad Usmani on a Study of Cilta-Cel Safety

What is the background of this study? 

CARTITUDE-1 (NCT03548207) is a phase Ib/II study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single-domain antibodies, in patients with relapsed refractory multiple myleoma. This study reports on the updated results in patients with a longer duration (median 12.4 months) of follow-up.  

In this video: 

Dr. Saad Usmani (Levine Cancer Institute/Atrium Health, Charlotte, NC) explains this study focused on characterizing cilta-cel safety, confirming the recommended phase II dose (recommended phase II dose; phase Ib), and evaluating efficacy (phase II) of this line of treatment. Cytokine release syndrome (CRS) and neurotoxicity were both observed. 

 Conclusions: 

A single infusion of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with multiple myeloma, with a manageable safety profile at the recommended phase II dose. Cilta-cel is under further investigation in other mulitple myeloma populations in earlier lines of therapy and in outpatient settings.  

 Clinical trial information: NCT03548207 

 

Video
IMF TV Blog Category

Source URL: https://www.myeloma.org/videos/ciltacabtagene-autoleucel-bcma-directed-cart-therapy-relapsed-refractory-multiple-myeloma-cartitude1